Christina K Baumgartner, Hakimeh Ebrahimi-Nik, Arvin Iracheta-Vellve, Keith M Hamel, Kira E Olander, Thomas G R Davis, Kathleen A McGuire, Geoff T Halvorsen, Omar I Avila, Chirag H Patel, Sarah Y Kim, Ashwin V Kammula, Audrey J Muscato, Kyle Halliwill, Prasanthi Geda, Kelly L Klinge, Zhaoming Xiong, Ryan Duggan, Liang Mu, Mitchell D Yeary, James C Patti, Tyler M Balon, Rebecca Mathew, Carey Backus, Domenick E Kennedy, Angeline Chen, Kenton Longenecker, Joseph T Klahn, Cara L Hrusch, Navasona Krishnan, Charles W Hutchins, Jax P Dunning, Marinka Bulic, Payal Tiwari, Kayla J Colvin, Cun Lan Chuong, Ian C Kohnle, Matthew G Rees, Andrew Boghossian, Melissa Ronan, Jennifer A Roth, Meng-Ju Wu, Juliette S M T Suermondt, Nelson H Knudsen, Collins K Cheruiyot, Debattama R Sen, Gabriel K Griffin, Todd R Golub, Nabeel El-Bardeesy, Joshua H Decker, Yi Yang, Magali Guffroy, Stacey Fossey, Patricia Trusk, Im-Meng Sun, Yue Liu, Wei Qiu, Qi Sun, Marcia N Paddock, Elliot P Farney, Mark A Matulenko, Clay Beauregard, Jennifer M Frost, Kathleen B Yates, Philip R Kym, Robert T Manguso
Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2 . The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators of inflammation, and their genetic deletion in either tumour cells or immune cells promotes anti-tumour immunity3-6 . However, phosphatases are challenging drug targets; in particular, the active site has been considered undruggable. Here we present the discovery and characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PTPN1 active-site inhibitor...
October 4, 2023: Nature